WESTMINSTER, Colo.,
June 25, 2012 /PRNewswire/
-- GeneThera Inc. (OTCQB: GTHR) is pleased to announce
that Applied Genetics, GeneThera's majority owned subsidiary, has
initiated commercial operation of its molecular diagnostic
laboratory based in Monterrey,
Mexico. Applied Genetics molecular diagnostic laboratory is
the first molecular laboratory in Mexico, to date, which is capable to detect
Johne's disease at the molecular level in milk, blood, and feces
from dairy cows, goats and sheep infected with the disease using
state-of-the-art molecular technology. Applied Genetics utilizes
GeneThera proprietary Johne's disease HerdCheck™ Field Collection
System (FCS) Molecular Assay. Dr. Tony
Milici, interim president of Applied Genetics and CEO of
GeneThera, stated; "The starting of Applied Genetics commercial
operation is a great success for GeneThera. I think it is
pretty remarkable that we were able to accomplish our goal in less
than 18 months. This achievement was made possible thanks to the
commitment and dedication of the Company's management and the
outstanding support of our loyal investors and collaborators. I
have to thank deeply all the people who believed in the Company and
its ability to achieve its goals; I am grateful."
Nutrition Avanzada, GeneThera's exclusive buyer and distributor
of the proprietary Johne's disease molecular system in Mexico, has entered into an agreement with a
large veterinary laboratory in Northern
Mexico. This agreement will provide access to about 20,000
animals initially. These animals will be tested for the presence of
mycobacterium paratuberculosis in milk, blood and feces.
Positive animals will be tested every 3 months to monitor progress
of the disease. The cost of the test will range from US
$30.00 – $32.00. In addition, Nutrition Avanzada is in the
final negotiation stages with two of the largest dairy companies in
Mexico.
As previously announced Nutricion Avanzada will purchase the
Johne's disease Field Collection System kit from Applied Genetics
and resell it directly to third parties. Samples will be then
shipped to Applied Genetics laboratory for processing. The
commercial operation will be implemented in Three (3) Phases:
during the current initial Phase (Phase I), Applied Genetics target
is to process a maximum of 100 samples/daily. Phase II, to be
initiated in late fall of 2012, will increase Applied Genetics
sample process throughput to 1500 samples/daily. Phase II will be
implemented in the early part of 2013, which will further increase
sample throughput to over 2000 samples daily.
Johne's disease is a global devastating and incurable disease of
dairy cows, sheep and goats caused by a bacterium called
Mycobacterium Paratuberculosis sub. Avium, (MAP). Dairy
products, contaminated with MAP, are the vehicles by which the
infection spreads in the human intestine triggering the onset of
Crohn's disease. Applied Genetics employs the use of GeneThera
HerdCheck™ to test and control the spread of Johne's disease in
Mexico. HerdCheck™ is a proprietary molecular diagnostic
system based on the use of high throughput robotics and Real time
PCR.
About GeneThera, Inc.
GeneThera, Inc. is a molecular biotechnology company located in
Westminster, Colorado. The
Company's proprietary diagnostic solution is based on a genetic
expression system, GES™ and Johne's disease management system,
HERDCHECK™ designed to function on a highly automated Fluorogenic
PCR platform. This platform enables GeneThera to offer tests that
are presently not available from other technologies. The GES™ and
HERDCHECK™ systems are designed for a host of individual diseases,
the current priority being Johne's disease. For more information,
contact Dr. Tony Milici at
720-439-3011. http://www.genethera.net
This press release contains forward-looking statements, which
are made pursuant to the Safe-Harbor provisions of the Private
Securities Litigation Reform Act of 1995. Words such as "intends,"
"believes," and similar expressions reflecting something other than
historical fact are intended to identify forward-looking
statements, but are not the exclusive means of identifying such
statements. These forward-looking statements involve a number of
risks and uncertainties, including the timely development and
market acceptance of products and technologies, the ability to
secure additional sources of finance, the ability to reduce
operating expenses, and other factors described in the Company's
filings with the Securities and Exchange Commission. The actual
results that the Company achieves may differ materially from any
forward-looking statement due to such risks and uncertainties. The
Company undertakes no obligation to revise or update any
forward-looking statements in order to reflect events or
circumstances that may arise after the date of this release.
GeneThera, Inc
SOURCE GeneThera, Inc.
